AbbVie Launches Phase 2 Trial of Venetoclax in Rare Blood Cancers

AbbVie is running a Phase 2 study in Japan to test venetoclax in adults with relapsed or refractory Waldenström macroglobulinemia or lymphoplasmacytic lymphoma, two rare blood cancers. The goal is to see how much the disease activity changes with this oral drug and whether it offers a new option where current treatments are limited.

The study tests venetoclax, an oral cancer medicine designed to trigger cancer cell death by blocking a key survival pathway. It is already used in other blood cancers, and here AbbVie aims to show it can help this small but underserved patient group as a stand-alone treatment.

The trial uses a single treatment group, so every participant receives venetoclax with no placebo or comparison arm. There is no blinding, meaning doctors and patients know they are getting the study drug, and the main purpose is direct treatment rather than prevention or diagnosis.

The study started after first submission on 28 January 2026, and is planned to run for about 28 months, with a primary completion date likely in late 2028. The most recent protocol update was filed on 2 March 2026, signaling that the design and operational plans are current.

This update reinforces AbbVie's push to expand venetoclax into niche blood cancers, which could support durable revenue from oncology beyond current indications. While the patient pool is small and near-term sales impact modest, positive data could strengthen the company's franchise versus rivals in hematology and add to the company's innovation story.

The study remains active and under way, with ongoing updates and full protocol details available on the ClinicalTrials.gov portal.

In recent financial results, AbbVie reported stronger-than-expected revenue and EPS, posted record net sales and provided FY-2026 EPS guidance that sits above consensus. The company has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS.

AbbVie reported quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. Revenue for the quarter was up 10.0% compared to the same quarter last year. During the same period in the previous year, the business earned $2.16 earnings per share.

Shares of AbbVie stock opened at $231.57 on Monday. The business has a fifty day simple moving average of $223.56 and a 200-day simple moving average of $221.07. The firm has a market cap of $409.28 billion, a price-to-earnings ratio of 98.12, a price-to-earnings-growth ratio of 0.81 and a beta of 0.35. AbbVie has a fifty-two week low of $164.39 and a fifty-two week high of $244.81.